Azalive 100mg Injection contains Azacitidine, a chemotherapy medication classified under nucleoside metabolic inhibitors. It is primarily used in adults for the treatment of Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML), especially in patients who are not suitable candidates for stem cell transplantation.

In MDS, the bone marrow produces faulty blood cells, while in AML, the bone marrow releases immature, non-functional white blood cells into the bloodstream. This medicine works by controlling abnormal cell growth in the bone marrow and improving blood cell production.

Before starting therapy, let your doctor know if you have a history of liver problems, kidney issues, or lung disorders. It’s also important to inform your doctor about any infections, allergies, or ongoing medications.

Doctors may prescribe Azalive 100mg Injection for:

• Treatment of Acute Myeloid Leukemia (AML) in patients with 20–30% blasts, especially those ineligible for stem cell transplant

• Intermediate-2 and High-risk categories of Myelodysplastic Syndrome (MDS)

For patients who cannot tolerate this medicine, your doctor may consider Azalive 100mg Injection alternatives.

The Azalive injection works by altering the DNA inside cancerous bone marrow cells. It reduces DNA methylation, a chemical process that can switch off tumor-suppressor genes. By inhibiting this process, Azalive 100mg Injection composition allows the body to restart the production of healthy blood cells and slow the growth of abnormal cells.

Additionally, it incorporates into RNA and DNA within rapidly dividing cells, disrupting their function and causing cell death in cancer cells.

Before starting Azalive 100mg Injection, inform your doctor about all the medicines you take, including:

• Prescription drugs for infections, heart disease, or seizures

• Over-the-counter medicines

• Vitamin and nutritional supplements

• Herbal products

Drug interactions may increase the risk of side effects or reduce the medicine's effectiveness. Close monitoring is required if used with other chemotherapy agents or blood thinners.

• Store Azalive 100mg Injection at room temperature (15°C to 30°C)

• Once reconstituted, use the solution immediately. If delayed, store it at 2°C to 8°C and use within 8 hours

• Keep out of sight and reach of children.

Azalive 100mg Injection is administered subcutaneously (under the skin) by a trained healthcare professional. The injection site is typically the thigh, stomach, or upper arm.

Your doctor will calculate your dose based on your height, weight, and overall health condition. Do not attempt to self-administer this medication.

Every medicine affects people differently. While using Azalive 100mg Injection, you may experience:

Common side effects:

• Nausea, vomiting, or diarrhea

• Constipation

• Fatigue

• Loss of appetite

• Dizziness

• Headache

• Pain at the injection site

• Sore throat or runny nose

• Joint or muscle pain

• Low blood counts (Anemia, low platelets, low white cells)

Serious side effects:

• Unexplained bleeding (in stool or urine)

• Severe infections or pneumonia

• Allergic reactions (swelling, rash, difficulty breathing)

• Seizures or severe headache

• Signs of kidney or liver problems

Report any unusual or severe symptoms to your doctor immediately.

• Stay well-hydrated to minimize side effects.

• Regular blood tests will be required to monitor your blood cell counts and organ functions.

• Avoid pregnancy or breastfeeding while on this medication.

• Do not self-administer the injection; it should always be given by a trained medical professional.

• Let your doctor know if you develop fever, unusual bleeding, or signs of infection.

• Maintain proper hand hygiene and avoid crowded places to reduce infection risk.

1. K. Gaston and P.-S. Jayaraman, Transcriptional repression in eukaryotes: Repressors and repression mechanisms, Cellular and Molecular Life Sciences, [May 2003], 60(4):721-741, [Accessed on 5th Apr 2021] https://www.researchgate.net/publication/7094896_Transcriptional_repression_in_eukaryotes_Repressors_and_repression_mechanisms
2. Roman M. Shapiro & Alejandro Lazo-Langner, Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia, BMC Hematology, 2018 [Accessed on 3rd Apr 2021] https://bmchematol.biomedcentral.com/articles/10.1186/s12878-017-0094-8
3. Dr.Reddy’s Laboratories, [Revised on 8th Nov 2018] [Accessed on 5th Apr 2021] https://www.drreddys.com/media/743001/ac-pm-english.pdf